Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
CGGR vs IBB: how they differ
CGGR and IBB hold 4% of their weight in the same names, and IBB returned more over the year.
Capital Group Growth ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, CGGR and IBB hold 4% of their money in the same securities at the same weight.
| Holding | CGGR | IBB |
|---|---|---|
| Vertex Pharmaceuticals Inc | 1.56% | 8.09% |
| Alnylam Pharmaceuticals Inc | 0.76% | 3.12% |
| Amgen Inc | 0.53% | 7.84% |
| Moderna Inc | 0.39% | 1.99% |
| Ionis Pharmaceuticals Inc | 0.36% | 1.00% |
| Only in CGGR | Only in IBB |
|---|---|
| Meta Platforms Inc 7.09% | Gilead Sciences, Inc. 6.85% |
| Tesla Inc 5.85% | Regeneron Pharmaceuticals, Inc. 4.91% |
| Broadcom Inc 5.40% | Argenx SE 3.76% |
| NVIDIA Corp 5.16% | Natera, Inc. 2.89% |
| Micron Technology Inc 4.86% | Revolution Medicines, Inc. 2.78% |
| Microsoft Corp 4.38% | Biogen, Inc. 2.47% |
| Alphabet Inc 3.36% | Illumina, Inc. 2.07% |
| Alphabet Inc 3.06% | Insmed, Inc. 1.79% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| CGGR Capital Group Growth ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Capital | iShares |
| What it is | Growth | Biotechnology |
| Total return, 1 year | +7.2% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −10.3 pts | +24.0 pts |
| Expense ratio | 0.39% | 0.44% |
| Already in the S&P 500 | 80.6% | 35.6% |
| Holdings | 89 | 248 |
CGGR in plain words
CGGR is an index equity fund tracking the Growth. Over the year to Sep 11, 2026 it returned +7.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.39% a year. By its holdings filed for May 31, 2026, 81% of the fund by weight is stocks the S&P 500 also holds, across 89 positions, with the top ten at 44.2%.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, CGGR or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, CGGR returned +7.2% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, CGGR or IBB?
- CGGR charges 0.39% a year and IBB charges 0.44%, so CGGR is cheaper. Fees come from each fund's prospectus.
- How much do CGGR and IBB overlap with the S&P 500?
- By their latest filed holdings, 81% of CGGR and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 4% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, CGGR against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/CGGR-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources